|
1.
|
Latif F, Tory K, Gnarra J, et al:
Identification of the von Hippel-Lindau disease tumor suppressor
gene. Science. 260:1317–1320. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Young AC, Craven RA, Cohen D, et al:
Analysis of VHL gene alterations and their relationship to clinical
parameters in sporadic conventional renal cell carcinoma. Clin
Cancer Res. 15:7582–7592. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Nyhan MJ, O’Sullivan GC and McKenna SL:
Role of the VHL (von Hippel-Lindau) gene in renal cancer: a
multifunctional tumour suppressor. Biochem Soc Trans. 36:472–478.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Li L and Kaelin WG Jr: New insights into
the biology of renal cell carcinoma. Hematol Oncol Clin North Am.
25:667–686. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Flaherty KT and Puzanov I: Building on a
foundation of VEGF and mTOR targeted agents in renal cell
carcinoma. Biochem Pharmacol. 80:638–646. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Závada J, Závadová Z, Zat’ovičová M, Hyrsl
L and Kawaciuk I: Soluble form of carbonic anhydrase IX (CA IX) in
the serum and urine of renal carcinoma patients. Br J Cancer.
89:1067–1071. 2003.
|
|
7.
|
Aggelis V, Craven RA, Peng J, et al:
Proteomic identification of differentially expressed plasma
membrane proteins in renal cell carcinoma by stable isotope
labelling of a von Hippel-Lindau transfectant cell line model.
Proteomics. 9:2118–2130. 2009. View Article : Google Scholar
|
|
8.
|
Craven RA, Hanrahan S, Totty N, et al:
Proteomic identification of a role for the von Hippel Lindau tumour
suppressor in changes in the expression of mitochondrial proteins
and septin 2 in renal cell carcinoma. Proteomics. 6:3880–3893.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Zhao Y, Zhang W, Kho Y and Zhao Y:
Proteomic analysis of integral plasma membrane proteins. Anal Chem.
76:1817–1823. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Shilov IV, Seymour SL, Patel AA, et al:
The Paragon Algorithm, a next generation search engine that uses
sequence temperature values and feature probabilities to identify
peptides from tandem mass spectra. Mol Cell Proteomics.
6:1638–1655. 2007. View Article : Google Scholar
|
|
11.
|
Rice P, Longden I and Bleasby A: EMBOSS:
the European Molecular Biology Open Software Suite. Trends Genet.
16:276–277. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Lockhart DJ, Dong H, Byrne MC, et al:
Expression monitoring by hybridization to high-density
oligonucleotide arrays. Nat Biotechnol. 14:1675–1680. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Bolstad BM, Irizarry RA, Åstrand M and
Speed TP: A comparison of normalization methods for high density
oligonucleotide array data based on variance and bias.
Bioinformatics. 19:185–193. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Irizarry RA, Bolstad BM, Collin F, Cope
LM, Hobbs B and Speed TP: Summaries of Affymetrix GeneChip probe
level data. Nucleic Acids Res. 31:e152003. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Smyth GK: Linear models and empirical
Bayes methods for assessing differential expression in microarray
experiments. Stat Appl Genet Mol Biol. 3:Article 3. 2004 View Article : Google Scholar
|
|
16.
|
Smyth GK: Limma: linear models for
microarray data. Bioinformatics and Computational Biology Solutions
Using R and Bioconductor. Gentleman R, Carey VJ, Dudoit S, Irizarry
RA and Huber W: Springer; New York, NY: pp. 397–420. 2005,
View Article : Google Scholar
|
|
17.
|
Sgambato A and Brancaccio A: The
dystroglycan complex: from biology to cancer. J Cell Physiol.
205:163–169. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Holt KH, Crosbie RH, Venzke DP and
Campbell KP: Biosynthesis of dystroglycan: processing of a
precursor propeptide. FEBS Lett. 468:79–83. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Jing J, Lien CF, Sharma S, Rice J, Brennan
PA and Górecki DC: Aberrant expression, processing and degradation
of dystroglycan in squamous cell carcinomas. Eur J Cancer.
40:2143–2151. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Losasso C, Di Tommaso F, Sgambato A, et
al: Anomalous dystroglycan in carcinoma cell lines. FEBS Lett.
484:194–198. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Ananth S, Knebelmann B, Grüning W, et al:
Transforming growth factor β1 is a target for the von Hippel-Lindau
tumor suppressor and a critical growth factor for clear cell renal
carcinoma. Cancer Res. 59:2210–2216. 1999.
|
|
22.
|
Nakamura E, Abreu-e-Lima P, Awakura Y, et
al: Clusterin is a secreted marker for a hypoxia-inducible
factor-independent function of the von Hippel-Lindau tumor
suppressor protein. Am J Pathol. 168:574–584. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Zatyka M, da Silva NF, Clifford SC, et al:
Identification of cyclin D1 and other novel targets for the von
Hippel-Lindau tumor suppressor gene by expression array analysis
and investigation of cyclin D1 genotype as a modifier in von
Hippel-Lindau disease. Cancer Res. 62:3803–3811. 2002.PubMed/NCBI
|
|
24.
|
Wykoff CC, Sotiriou C, Cockman ME, et al:
Gene array of VHL mutation and hypoxia shows novel hypoxia-induced
genes and that cyclin D1 is a VHL target gene. Br J Cancer.
90:1235–1243. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Jiang Y, Zhang W, Kondo K, et al: Gene
expression profiling in a renal cell carcinoma cell line:
dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res.
1:453–462. 2003.PubMed/NCBI
|
|
26.
|
Boysen G, Bausch-Fluck D, Thoma CR, et al:
Identification and functional characterization of pVHL-dependent
cell surface proteins in renal cell carcinoma. Neoplasia.
14:535–546. 2012.PubMed/NCBI
|
|
27.
|
Adam PJ, Terrett JA, Steers G, et al: CD70
(TNFSF7) is expressed at high prevalence in renal cell carcinomas
and is rapidly internalised on antibody binding. Br J Cancer.
95:298–306. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Yonally SK and Capaldi RA: The F(1)F(0)
ATP synthase and mitochondrial respiratory chain complexes are
present on the plasma membrane of an osteosarcoma cell line: an
immunocytochemical study. Mitochondrion. 6:305–314. 2006.
View Article : Google Scholar
|
|
29.
|
Shin BK, Wang H, Yim AM, et al: Global
profiling of the cell surface proteome of cancer cells uncovers an
abundance of proteins with chaperone function. J Biol Chem.
278:7607–7616. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Jang JH and Hanash S: Profiling of the
cell surface proteome. Proteomics. 3:1947–1954. 2003. View Article : Google Scholar
|
|
31.
|
Tjalsma H, Pluk W, van den Heuvel LP,
Peters WH, Roelofs R and Swinkels DW: Proteomic inventory of
‘anchorless’ proteins on the colon adenocarcinoma cell surface.
Biochim Biophys Acta. 1764:1607–1617. 2006.
|
|
32.
|
Sgambato A, Migaldi M, Montanari M, et al:
Dystroglycan expression is frequently reduced in human breast and
colon cancers and is associated with tumor progression. Am J
Pathol. 162:849–860. 2003. View Article : Google Scholar
|
|
33.
|
Sgambato A, Caredda E, Leocata P, et al:
Expression of alpha-dystroglycan correlates with tumour grade and
predicts survival in oral squamous cell carcinoma. Pathology.
42:248–254. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Jiang X, Rieder S, Giese NA, Friess H,
Michalski CW and Kleeff J: Reduced alpha-dystroglycan expression
correlates with shortened patient survival in pancreatic cancer. J
Surg Res. 171:120–126. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Moon YW, Rha SY, Zhang X, et al:
Increments of alpha-dystroglycan expression in liver metastasis
correlate with poor survival in gastric cancer. J Surg Oncol.
100:459–465. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Sgambato A, De Paola B, Migaldi M, et al:
Dystroglycan expression is reduced during prostate tumorigenesis
and is regulated by androgens in prostate cancer cells. J Cell
Physiol. 213:528–539. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Sgambato A, Camerini A, Amoroso D, et al:
Expression of dystroglycan correlates with tumor grade and predicts
survival in renal cell carcinoma. Cancer Biol Ther. 6:1840–1846.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Sgambato A, Camerini A, Genovese G, et al:
Loss of nuclear p27kip1 and alpha-dystroglycan is a
frequent event and is a strong predictor of poor outcome in renal
cell carcinoma. Cancer Sci. 101:2080–2086. 2010.
|
|
39.
|
Calogero A, Pavoni E, Gramaglia T, et al:
Altered expression of alpha-dystroglycan subunit in human gliomas.
Cancer Biol Ther. 5:441–448. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Shimojo H, Kobayashi M, Kamigaito T,
Shimojo Y, Fukuda M and Nakayama J: Reduced glycosylation of
alpha-dystroglycans on carcinoma cells contributes to formation of
highly infiltrative histological patterns in prostate cancer.
Prostate. 71:1151–1157. 2011. View Article : Google Scholar
|
|
41.
|
de Bernabé DB, Inamori K,
Yoshida-Moriguchi T, et al: Loss of alpha-dystroglycan laminin
binding in epithelium-derived cancers is caused by silencing of
LARGE. J Biol Chem. 284:11279–11284. 2009.PubMed/NCBI
|
|
42.
|
Bao X, Kobayashi M, Hatakeyama S, et al:
Tumor suppressor function of laminin-binding alpha-dystroglycan
requires a distinct beta3-N-acetylglucosaminyltransferase. Proc
Natl Acad Sci USA. 106:12109–12114. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Henry MD, Cohen MB and Campbell KP:
Reduced expression of dystroglycan in breast and prostate cancer.
Hum Pathol. 32:791–795. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Cross SS, Lippitt J, Mitchell A, et al:
Expression of beta-dystroglycan is reduced or absent in many human
carcinomas. Histopathology. 53:561–566. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Parberry-Clark C, Bury JP, Cross SS and
Winder SJ: Loss of dystroglycan function in oesophageal cancer.
Histopathology. 59:180–187. 2011.PubMed/NCBI
|
|
46.
|
Shang ZJ, Ethunandan M, Górecki DC and
Brennan PA: Aberrant expression of beta-dystroglycan may be due to
processing by matrix metalloproteinases-2 and -9 in oral squamous
cell carcinoma. Oral Oncol. 44:1139–1146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Yamada H, Saito F, Fukuta-Ohi H, et al:
Processing of beta-dystroglycan by matrix metalloproteinase
disrupts the link between the extracellular matrix and cell
membrane via the dystroglycan complex. Hum Mol Genet. 10:1563–1569.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Zhong D, Saito F, Saito Y, Nakamura A,
Shimizu T and Matsumura K: Characterization of the protease
activity that cleaves the extracellular domain of
beta-dystroglycan. Biochem Biophys Res Commun. 345:867–871. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Bozzi M, Inzitari R, Sbardell D, et al:
Enzymatic processing of beta-dystroglycan recombinant ectodomain by
MMP-9: identification of the main cleavage site. IUBMB Life.
61:1143–1152. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Sotgia F, Bonuccelli G, Bedford M, et al:
Localization of phospho-beta-dystroglycan (pY892) to an
intracellular vesicular compartment in cultured cells and skeletal
muscle fibers in vivo. Biochemistry. 42:7110–7123. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
James M, Nuttall A, Ilsley JL, et al:
Adhesion-dependent tyrosine phosphorylation of beta-dystroglycan
regulates its interaction with utrophin. J Cell Sci. 113:1717–1726.
2000.PubMed/NCBI
|
|
52.
|
Mitchell A, Mathew G, Jiang T, et al:
Dystroglycan function is a novel determinant of tumor growth and
behavior in prostate cancer. Prostate. 73:398–408. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Almaraz RT, Tian Y, Bhattarcharya R, et
al: Metabolic flux increases glycoprotein sialylation: implications
for cell adhesion and cancer metastasis. Mol Cell Proteomics.
11:M112.0175582012. View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Keppler OT, Hinderlich S, Langner J,
Schwartz-Albiez R, Reutter W and Pawlita M: UDP-GlcNAc 2-epimerase:
a regulator of cell surface sialylation. Science. 284:1372–1376.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
55.
|
Möller H, Böhrsch V, Lucka L, Hackenberger
CP and Hinderlich S: Efficient metabolic oligosaccharide
engineering of glycoproteins by UDP-N-acetylglucosamine
2-epimerase/N-acetylmannosamine kinase (GNE) knock-down. Mol
Biosyst. 7:2245–2251. 2011.PubMed/NCBI
|
|
56.
|
Kemmner W, Kessel P, Sanchez-Ruderisch H,
et al: Loss of UDP-N-acetylglucosamine
2-epimerase/N-acetylmannosamine kinase (GNE) induces apoptotic
processes in pancreatic carcinoma cells. FASEB J. 26:938–946. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, et al: Oncomine 3.0: genes, pathways, and networks in a
collection of 18,000 cancer gene expression profiles. Neoplasia.
9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
André S, Sanchez-Ruderisch H, Nakagawa H,
et al: Tumor suppressor p16INK4a - modulator of glycomic
profile and galectin-1 expression to increase susceptibility to
carbohydrate-dependent induction of anoikis in pancreatic carcinoma
cells. FEBS J. 274:3233–3256. 2007.
|
|
59.
|
Meany DL and Chan DW: Aberrant
glycosylation associated with enzymes as cancer biomarkers. Clin
Proteomics. 8:72011. View Article : Google Scholar : PubMed/NCBI
|
|
60.
|
Brooks SA, Carter TM, Royle L, et al:
Altered glycosylation of proteins in cancer: what is the potential
for new anti-tumour strategies. Anticancer Agents Med Chem. 8:2–21.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
61.
|
Ferguson RE, Vasudev NS, Selby PJ and
Banks RE: Protein glycosylation and renal cancer. Encyclopedia of
Genetics, Genomics, Proteomics and Bioinformatics. Jorde LB, Little
P, Dunn M and Subramaniam S: John Wiley and Sons; 2006, View Article : Google Scholar
|
